CryoTherapeutics GmbH, a Cologne, Germany-based developer of a proprietary cryotherapy system for use in the treatment of coronary artery disease, completed an extension to its Series A financing bringing the total of the round to €6.5m.
The round was led by Peppermint Venture Partners (PVP) via its Charité Biomedical Fund with participation from existing investors NRW.BANK, Rainer Christine Asset Management GmbH, High-Tech Gründerfonds (HTGF) and Getz Brothers and new investor KfW.
Established in December 2009 and led by Led by Maurice Buchbinder MD, Chief Medical Officer, and John Yianni PhD, Managing Director, CryoTherapeutics is focusing on developing a novel catheter system, which utilizes cryoenergy to treat and prevent heart attacks. The initial objective of the company is the demonstration of the clinical benefit in the treatment of heart attack patients using this catheter-based system that will be utilized by interventional cardiologists.
21/03/2013: CryoTherapeutics Raises Additional Series A Funding